4YVE

ROCK 1 bound to methoxyphenyl thiazole inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.4 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.218 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.

Green, J.Cao, J.Bandarage, U.K.Gao, H.Court, J.Marhefka, C.Jacobs, M.Taslimi, P.Newsome, D.Nakayama, T.Shah, S.Rodems, S.

(2015) J.Med.Chem. 58: 5028-5037

  • DOI: 10.1021/acs.jmedchem.5b00424
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The Rho kinases (ROCK1 and ROCK2) are highly homologous serine/threonine kinases that act on substrates associated with cellular motility, morphology, and contraction and are of therapeutic interest in diseases associated with cellular migration and ...

    The Rho kinases (ROCK1 and ROCK2) are highly homologous serine/threonine kinases that act on substrates associated with cellular motility, morphology, and contraction and are of therapeutic interest in diseases associated with cellular migration and contraction, such as hypertension, glaucoma, and erectile dysfunction. Beginning with compound 4, an inhibitor of ROCK1 identified through high-throughput screening, systematic exploration of SAR, and application of structure-based design, led to potent and selective ROCK inhibitors. Compound 37 represents significant improvements in inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable for in vivo experimentation.


    Related Citations: 
    • The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
      Jacobs, M.,Hayakawa, K.,Swenson, L.,Bellon, S.,Fleming, M.,Taslimi, P.,Doran, J.
      (2006) J. Biol. Chem. 281: 260
    • ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
      Gao, H.,Marhefka, C.,Jacobs, M.D.,Cao, J.,Bandarage, U.K.,Green, J.
      (2018) Bioorg. Med. Chem. Lett. --: --


    Organizational Affiliation

    †Vertex Pharmaceuticals, Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Rho-associated protein kinase 1
A, B
415Homo sapiensMutation(s): 0 
Gene Names: ROCK1
EC: 2.7.11.1
Find proteins for Q13464 (Homo sapiens)
Go to Gene View: ROCK1
Go to UniProtKB:  Q13464
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
4KK
Query on 4KK

Download SDF File 
Download CCD File 
A, B
2-(3-methoxyphenyl)-N-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]acetamide
C17 H15 N3 O2 S
GOPDRFODUBCWMB-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
4KKKi: 100 nM (100) BINDINGDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.4 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.218 
  • Space Group: P 31 2 1
Unit Cell:
Length (Å)Angle (°)
a = 181.980α = 90.00
b = 181.980β = 90.00
c = 90.560γ = 120.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
BUSTER-TNTrefinement
d*TREKdata scaling
d*TREKdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2015-03-19 
  • Released Date: 2015-06-10 
  • Deposition Author(s): Jacobs, M.D.

Revision History 

  • Version 1.0: 2015-06-10
    Type: Initial release
  • Version 1.1: 2015-06-17
    Type: Database references
  • Version 1.2: 2015-07-08
    Type: Data collection
  • Version 1.3: 2018-07-18
    Type: Data collection, Database references, Derived calculations, Source and taxonomy